Archive | November, 2023

Hot Investor Mandate: Western Europe-Based Firm Invests Broadly Across All Life Science Sectors, Preferring to Engage in Pre-Seed to Series A Rounds

16 Nov

An investment fund located in Western Europe focuses on early-stage life science investments, more specifically in drug development, medical devices, and diagnostics. The fund makes Pre-Seed, Seed, and Series A investments with an investment sweet spot of around €1.5 M. The maximum investment in one project can be €5.3 M in several rounds, preferentially in equity investments. The firm is led by an experienced team of professionals with backgrounds in private equity, the healthcare industry, and venture capital, who can support entrepreneurs on their journey to global success. Thanks to close cooperation with the fund’s main sponsor, a leading biotech incubator, the firm has a great opportunity to be at the origin of transformative Central European technologies.

The firm is seeking opportunities in drug development, medical devices, diagnostics, and other life sciences. The firm is agnostic to subsectors and indications, and expects to see some pre-clinical data (ideally in vivo PoC) from the start-up companies, to consider investment.

The firm is open to all types of management teams. The firm can lead the investment round under specific circumstances, or co-invest and will seek a board seat when leading. The firm prefers to syndicate for all of their investments.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: VC Firm Invests in North America-Based Deeptech Companies, Including Healthcare Companies Addressing the Aging and Chronic Diseases Market

16 Nov

A venture capital firm founded in 2016 with a primary office in the US will soon be investing from a third fund, dedicated towards seed-stage companies that solve the most critical problems of today. The typical check size is around $1M USD and the firm expects to invest in 4-6 companies in the next year. The firm invests globally with a focus on North America.

The firm is mainly focused on deep tech opportunities related to prevalent industrial, agriculture, climate, and healthcare issues. Within healthcare, the firm is primarily interested in scalable technologies that assist the aging population and chronic diseases and address rising healthcare costs. The firm is open to all modalities within the diagnostics, medical devices, and biomanufacturing spaces, but does not invest in therapeutics. Though opportunistic, the firm looks for technology in development phases that can seamlessly be integrated into workflows and meet the existing market demand. The firm is open to all indications related to the aging population and chronic disease, including renal health, heart disease, and oncology.

The firm is looking for coachable, open-minded, and growth-centered management teams. The firm will typically lead and require board seat to work closely with companies. However, co-leading and syndicate investments are also feasible.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: Government-Backed Firm Seeks Investment and Partnership Opportunities With Global, Prototype-Ready Medical Device Companies

16 Nov

Founded in 2019, a China-based firm sponsored by the local municipal government focuses on investment, BD and other forms of collaboration with disruptive medical technologies. With in-depth experience from their teams covering R&D, registration, distribution and sales in China and around the world, the group is looking for domestic and cross-border partnerships in terms of investment, license-in, joint venture, distribution and others.

The firm focuses on Class II and Class III medical devices from in-development to commercialization stage, especially prototype-ready projects. The firm pays special attention to companies that are developing projects related to neuro-surgery, endoscope and minimally invasive devices, stroke, cardiovascular disease, eye disease, medical robots, etc.

The firm prefers companies with a Chinese angle and are open to discussing China rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Have a Great Tagline? Submit and Win RESI JPM Tickets!

9 Nov

By Caitlin Dolegowski, Marketing Manager, LSN

Life Science Nation (LSN)’s preparation for RESI JPM is in full swing. As we prepare for our flagship Redefining Early Stage Investments (RESI) conference during JP Morgan Healthcare week in San Francisco, in-person January 9 at the historic Marine’s Memorial Hotel, followed by two days of virtual partnering. LSN works with early-stage startups in educational boot camps, free online webinars, consulting, etc. The TAGLINE is a key component in our messaging to our clients in preparation for perfecting their pitch.

The Tagline: The Foundation of Your Message. The tagline details your company’s identity in a single line; getting this right requires attention to detail. Every entrepreneur should be able to describe their company in 5-8 words. Ideally, a tagline will address the company’s technology modality, its indication procedure, and what makes you unique. A good tagline is crucial to leave a good first impression and allows investors to quickly determine if your technology aligns with their interests. How do you distill your identity into a single line and make the right first impression to potential investors?

Submit your tagline! Life Science Nation will evaluate and name the top 3 tagline winners. Winners will win a free RESI JPM registration (a standard 3-day registration, including in-person partnering on Tuesday, January 9, and two days of virtual partnering on January 10-11). We will announce our winners and promote your tagline here in our Next Phase newsletter to be seen by LSN’s 45K+ readership. Winners will be announced Wednesday, November 22.  Submit by Friday, November 17.

Submit Your Tagline

RESI-SF-2024-Banner-1100

Crafting an Effective IP Strategy: Guiding Capital Investors and Licensing Partners Toward Your Innovation

9 Nov

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

In the dynamic world of innovation, having a robust Intellectual Property (IP) strategy is paramount. Not only does it serve as a shield to safeguard your groundbreaking ideas, but it also acts as a magnet, drawing investors and licensing partners, fostering relationships, and bestowing your venture with a competitive edge. In this article, we will delve into the intricacies of an IP strategy, examining its pivotal role and how it intersects with patents. In addition, we’ll be able to guide you through understanding your IP context, effectively communicating your innovation’s essence, and helping you decide the right type of IP protection and filing strategy. Finally, we will explore the nexus between IP valuation and its impact on your startup’s potential success.

Let’s Start with a Simple Question

Why an IP Strategy is Important? Here are the main areas of consideration in understanding your startup’s IP. Protect an invention; intellectual property rights, such as patents, offer legal protection for your invention, preventing others from using, making, or selling it without your consent. Attracting investors with a well-defined IP strategy can be a powerful attraction for investors, assuring them that your innovation is secure and has the potential for substantial returns. Secure partnerships leveraging robust IP protection can pave the way for fruitful collaborations and partnerships, as potential partners will see the value in working with an entity that can safeguard their interests. Establish a competitive advantage; a sound IP strategy can give you a competitive advantage by ensuring competitors can’t easily replicate your innovation.

Understanding the Intersection of Patents and IP

Do you have a novel invention or innovation? Can you assess whether your creation is unique and qualifies for patent protection? Please keep in mind that timing is critical for patent applications. Filing too early or too late can be detrimental. Strategic timing can also help you avoid costly legal battles. As with regulatory compliance, you must stay aware of compliance issues, ensuring that your innovation meets legal requirements.

Getting in Context with Your Value

IP can encompass various elements, from inventions and innovations to trade secrets, data, and proprietary know-how. You need to assess and prioritize the importance and value of each facet of your IP to focus your resources effectively. Once you truly understand where the heart of your IP is, you then need to be able to deliver that message to capital investors and licensing partners. This means you need to get your story straight by taking the time to craft a coherent narrative that encapsulates the essence of your innovation. Once you have your compelling IP narrative, you need to be able to communicate that value effectively. Practice and learn how to convey your innovation’s value to the broader marketplace in a cogent, lucid, and simple story.

Determining What You Need

Could you assess whether your innovation warrants patent protection? This is particularly relevant if your innovation is a new and useful process, machine, or composition of matter. Copyright may apply to creative works like literature, music, and software. If your innovation relies on confidential information, trade secrets can be a valuable form of protection. In some cases, a combination of different types of IP protection may be necessary to cover all aspects of your innovation.

Global Filing Strategy, Valuation, and IP are All Intertwined.

Decide on the scope of your IP protection. Regional, national, or international protection options vary in coverage and complexity.  Often, early on in a company’s journey, you will have to deal with exclusive arrangements for specific regions or territories; you must know how to navigate and guide your IP through those challenges that can make or break your company. Global distribution, valuation, and IP are combined with your product’s location in the market. Are your products iterative, better, faster, or cheaper than the current standard of care in the marketplace, or does your product leapfrog, creating a new standard of care from the market by going from invasive to noninvasive or going from intravenous to pill form, or is it disruptive like reprogramming and repairing mutated genes and curing heretofore incurable diseases?

By understanding the nuances of your IP, effectively communicating its value, and selecting the appropriate IP protection and filing strategy, you can pave the way for success in the competitive innovation landscape. Furthermore, recognizing the intertwining relationship between IP valuation and your innovation’s potential can be the key to attracting the right investors and partners to help your venture thrive.

RESI-SF-2024-Banner-1100

Life Science Nation Announces Free Webinar Series In Preparation for RESI JPM

9 Nov

By Karen Deyo, VP of Product, Israel BD, LSN

Life Science Nation (LSN) is happy to announce our webinar schedule leading up to our next RESI conference, taking place in San Francisco, during JP Morgan Healthcare week. Featuring educational content put together by LSN to help early-stage startups with their fundraising campaigns, these webinars were designed to give companies the benefit of our experience, of working with startups and investors in the healthcare space for over a decade. This webinar series will also include a new session, and a fireside chat with investors with new funds who will be joining our LSN network. Make sure to mark these webinars on your calendars!

Tuesday, November 14, 12PM ET

Preparing for the Innovator’s Pitch Challenge (IPC) at RESI JPMSign Up

Maximizing your exposure to investors is critical to a successful fundraising campaign, and participating in pitch events plays a large role in that. The RESI Innovator’s Pitch Challenge has been designed to give companies a platform to promote their companies, practice their pitch, and get feedback from a panel of relevant investors and industry experts. Join this session to learn what you can gain from participating in the IPC and how to apply.


Tuesday, November 21, 12PM ET

Startup CEOs Global Partnering StrategySign Up

This session will cover some of the pitfalls that catch first-time and serial entrepreneurs off guard. From false premise and being tentative to surrounding yourself with executives who do not have augmentative and complimentary skillsets, many things can slow the growth of your early-stage life science entity. By learning how to avoid these issues and not run yourself over, your chances of making it to the market will increase greatly.


Tuesday, November 28, 12PM ET

Presenting to Investors: Compelling Story VS. Pitch DeckSign Up

The most successful entrepreneurs are always the best storytellers. Finding a way to formulate your company’s unique story naturally and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook.


Tuesday, December 5, 12PM ET

Partnering TutorialSign Up

Understanding the RESI partnering system and using it to its maximum capabilities can make a large difference in a company’s success at RESI. Join LSN staff as we walk you through our system and how it can help you identify partners who are a best fit for you, how to manage your outreach, our recommended strategy for following up, and how to take advantage of all of the content that we provide to ensure your best possible RESI experience.


Tuesday, December 12, 12PM ET

Fireside Chat with Three New Startups FundsSign Up

This Fireside Chat will feature investors representing new funds focusing on early-stage life science companies. Find out more about these funds joining the LSN ecosystem


Tuesday, December 19, 12PM ET

Partnering TutorialSign Up

Understanding the RESI partnering system and using it to its maximum capabilities can make a large difference in a company’s success at RESI. Join LSN staff as we walk you through our system and how it can help you identify partners who are a best fit for you, how to manage your outreach, our recommended strategy for following up, and how to take advantage of all of the content that we provide to ensure your best possible RESI experience.


Wednesday, January 3, 12PM ET

Developing Your Global Target List of Investors For RESI JPMSign Up

Find tools to aid in your search for investors to reach out to who are a fit based on your company type.

RESI-SF-2024-Banner-1100

Hot Investor Mandate: Europe Based Venture Capital Firm with Multiple Funds Under Management Invests Across Healthcare Sectors, Including Digital Health, Diagnostics, Medical Devices and More in the US, Europe and Israel

9 Nov

A venture capital firm was founded in 1997 and operates offices in Berlin, Munich, Istanbul, and London. With EUR 2 billion under management across all fund streams, 9 IPOs, and 31 trade sales, the firm is one of Europe’s most established and active venture capital firms. Its dedicated Health Fund leads or co-leads investments, typically with an initial investment of €4-6 million and an average of €6-12 million per company over the lifetime of the investment. The geographical focus is on companies across Europe and selectively in the US and Israel.

The firm focuses on technologies across healthcare sectors, including digital health, diagnostics, medical devices, R&D tools and biopharma, with the ultimate goal of delivering strong, positive patient outcomes.

The firm is open to investing in companies at early stages with proof-of-concept, clinically relevant data and/or strong IP positions.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.